New York, NY (PRWEB) January 23, 2014
The birth control safety center at DrugNews.net has added new information for women who have used the contraceptives Yaz or Yasmin. Recent court records show the number of patient lawsuits alleging side effects from the drugs have dropped slightly as cases are settled*.
DrugNews provides a free resource for patients taking popular prescription drugs, giving them the latest safety alerts, recalls, studies and legal news. Visitors can decide if they need to talk with their doctor about potential dangers and determine if they need legal advice.
The resource center has added health warnings for Yaz and Yasmin from experts such as the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone can increase the risk of blood clots.
Due to the amount of patients filing a claim over alleged blood clots and side effects, Yaz lawsuits were consolidated in a special federal Multi-District Litigation court. (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).
A DrugNews investigation found that Bayer, the maker of Yaz, has spent approximately $1.575 billion to settle around 7,660 lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT) from Yaz or Yasmin****.
Now, the resource center has learned the most recent records this month from the Judicial Panel on Multidistrict Litigation show the number of pending Yaz claims has dropped from 9,826 on December 16th to 9,781 as of January 15th*.
Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin can still contact the DrugNews Center or speak with a lawyer about their options. Due to the complexity of drug injury cases, DrugNews only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugNews.net.
*JPML 1/15/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-January-15-2014.pdf
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****Bayer Stockholder’s Newsletter, Explanatory Notes; Legal Risks, 10/31/13; stockholders-newsletter-q3-2013.bayer.com/en/explanatory-notes.aspx